...
首页> 外文期刊>BMC Medicine >CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
【24h】

CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients

机译:CD133 + CXCR4 +结肠癌细胞具有转移潜力并预测患者预后不良

获取原文

摘要

Background Colorectal cancer (CRC), which frequently metastasizes to the liver, is one of the three leading causes of cancer-related deaths worldwide. Growing evidence suggests that a subset of cells exists among cancer stem cells. This distinct subpopulation is thought to contribute to liver metastasis; however, it has not been fully explored in CRC yet. Methods Flow cytometry analysis was performed to detect distinct subsets with CD133 and CXCR4 markers in human primary and metastatic CRC tissues. The 'stemness' and metastatic capacities of different subpopulations derived from the colon cancer cell line HCT116 were compared in vitro and in vivo . The roles of epithelial-mesenchymal transition (EMT) and stromal-cell derived factor-1 ( SDF-1 ) in the metastatic process were also investigated. A survival curve was used to explore the correlation between the content of CD133+CXCR4+ cancer cells and patient survival. Results In human specimens, the content of CD133+CXCR4+ cells was higher in liver metastases than in primary colorectal tumors. Clonogenic and tumorigenic cells were restricted to CD133+ cells in the HCT116 cell line, with CXCR4 expression having no impact on the 'stemness' properties. We found that CD133+CXCR4+ cancer cells had a high metastatic capacity in vitro and in vivo . Compared with CD133+CXCR4- cells, CD133+CXCR4+ cancer cells experienced EMT, which contributed partly to their metastatic phenotype. We then determined that SDF-1 / CXCL12 treatment could further induce EMT in CD133+CXCR4+ cancer cells and enhance their invasive behavior, while this could not be observed in CD133+CXCR4- cancer cells. Blocking SDF-1 /CXCR4 interaction with a CXCR4 antagonist, AMD3100 (1,10-[1,4-phenylenebis(methylene)]bis-1,4,8,11 -tetraazacyclotetradecane octahydrochloride), inhibited metastatic tumor growth in a mouse hepatic metastasis model. Finally, a high percentage of CD133+CXCR4+ cells in human primary CRC was associated with a reduced two-year survival rate. Conclusions Strategies targeting the SDF-1 /CXCR4 interaction may have important clinical applications in the suppression of colon cancer metastasis. Further investigations on how high expression of CXCR4 and EMT occur in this identified cancer stem cell subset are warranted to provide insights into our understanding of tumor biology.
机译:背景结直肠癌(CRC)经常转移到肝脏,是全世界与癌症相关的死亡的三大主要原因之一。越来越多的证据表明,癌症干细胞中存在一部分细胞。据认为,这种独特的亚群有助于肝转移。但是,它尚未在CRC中得到充分探索。方法进行流式细胞术分析,以检测人原发性和转移性CRC组织中具有CD133和CXCR4标记的不同亚群。在体内和体外比较结肠癌细胞系HCT116衍生的不同亚群的'干性'和转移能力。还研究了上皮-间质转化(EMT)和基质细胞衍生因子-1(SDF-1)在转移过程中的作用。使用生存曲线探讨CD133 + CXCR4 + 癌症含量之间的相关性细胞和患者存活率。结果在人体标本中,肝转移中CD133 + CXCR4 + 细胞的含量较高比原发性大肠肿瘤要大。克隆和致瘤细胞仅限于HCT116细胞系中的CD133 + 细胞,而CXCR4的表达对“干性”特性没有影响。我们发现CD133 + CXCR4 + 癌细胞在体外和体外具有高转移能力。体内。与CD133 + CXCR4 -单元格相比,CD133 + CXCR4 + 癌细胞经历了EMT,部分导致了它们的转移表型。然后,我们确定SDF-1 / CXCL12处理可进一步诱导CD133 + CXCR4 + 癌细胞并增强其侵袭行为,而CD133 + CXCR4 -癌细胞。阻断SDF-1 / CXCR4与CXCR4拮抗剂AMD3100(1,10- [1,4-亚苯基双(亚甲基)] bis-1,4,8,11-四氮杂环十四烷八盐酸盐的相互作用)抑制了小鼠肝转移性肿瘤的生长。转移模型。最后,在人类原发性CRC中,高百分比的CD133 + CXCR4 + 细胞与降低了两年的生存率。结论针对SDF-1 / CXCR4相互作用的策略可能在抑制结肠癌转移中具有重要的临床应用。有必要进一步研究在鉴定出的癌症干细胞亚群中CXCR4和EMT的高表达情况,以便为我们对肿瘤生物学的理解提供见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号